| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, ... Nature medicine 24 (10), 1545-1549, 2018 | 670 | 2018 |
| WeSME: uncovering mutual exclusivity of cancer drivers and beyond YA Kim, S Madan, TM Przytycka Bioinformatics 33 (6), 814-821, 2017 | 84 | 2017 |
| BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions P Dao, YA Kim, D Wojtowicz, S Madan, R Sharan, TM Przytycka PLoS computational biology 13 (10), e1005695, 2017 | 51 | 2017 |
| CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 9 (58), 31264, 2018 | 12 | 2018 |
| Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer S Madan, S Sinha, T Chang, JS Gutkind, EEW Cohen, AA Schäffer, ... Cancers 15 (19), 4885, 2023 | 5 | 2023 |
| Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias N Sinha, S Sinha, K Cheng, S Madan, A Erez, BM Ryan, AA Schäffer, ... JCO precision oncology 5, PO. 21.00168, 2021 | 5 | 2021 |
| Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues N Sanghvi, C Calvo-Alcañiz, PS Rajagopal, S Scalera, V Canu, S Sinha, ... Science Advances 10 (49), eadn0220, 2024 | 4 | 2024 |
| A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials SK Silbert, S Madan, EM Holland, SM Steinberg, L Little, T Foley, ... Blood advances 7 (18), 5566-5578, 2023 | 2 | 2023 |
| Repurposing CAR targets in solid tumors from pan-cancer single-cell RNA-seq data S Madan, A Schäffer, E Ruppin Cancer Research 82 (12_Supplement), 2711-2711, 2022 | 1 | 2022 |
| The recently approved high-TMB criteria may introduce a sex bias in response to PD1 inhibitors N Sinha, S Sinha, K Cheng, S Madan, A Schaffer, K Aldape, A Erez, ... Cancer Research 81 (13_Supplement), 29-29, 2021 | 1 | 2021 |
| Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 10 (13), 1344, 2019 | 1 | 2019 |
| Magnetospectroscopy of CaF2: Dy2+ in the submillimeter∗ J Waldman, RW Stimets, SZ Madan, TS Chang Infrared Physics 18 (2), 141-146, 1978 | 1 | 1978 |
| Abstract A033: Identifying logic-gated combinatorial antigens from single-cell transcriptomics data of patient tumors for effective and safe CAR therapy design S Madan, T Chang, A Harris, H Liu, SR Dhruba, S Sinha, S Rajagopal, ... Cancer Research 85 (5_Supplement), A033-A033, 2025 | | 2025 |
| Single-cell-guided identification of logic-gated antigen combinations for designing effective and safe CAR therapy S Madan, T Chang, AR Harris, H Liu, A Martinez, SR Dhruba, B Wang, ... bioRxiv, 2025.03. 19.644074, 2025 | | 2025 |
| IMMClock reveals immune aging and T cell function at single-cell resolution YG Schmidt, D Wu, S Madan, S Sinha, S Sahni, V Gopalan, B Wang, ... bioRxiv, 2024.11. 13.623449, 2024 | | 2024 |
| Abstract LB245: Single cell guided identification of logic-gated cell surface combinations for selective and safe CAR therapy design S Madan, T Chang, B Wang, SR Dhruba, AA Schäffer, E Ruppin Cancer Research 84 (7_Supplement), LB245-LB245, 2024 | | 2024 |
| Unveiling the potential of bispecific antibodies: A comprehensive analysis of efficiency, toxicity, and repurposing in cancer treatment B Wang, S Madan, A Schaffer, E Ruppin Cancer Research 84 (6_Supplement), 871-871, 2024 | | 2024 |
| Cell-type-specific transcriptomic immune aging clocks reveal clinically relevant associations with chronic illnesses including cancer Y Gurevich-Schmidt, K Wang, D Wu, S Madan, V Gopalan, S Sinha, ... Cancer Research 84 (6_Supplement), 1411-1411, 2024 | | 2024 |
| Abstract B100: Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues N Sanghvi, C Calvo-Alcañiz, PS Rajagopal, S Sinha, F Schischlik, ... Molecular Cancer Therapeutics 22 (12_Supplement), B100-B100, 2023 | | 2023 |
| Abstract LB_B06: Single cell transcriptomics guided identification of antigen combinations for the design of logic-gated CAR therapies S Madan, T Chang, B Wang, AA Schäffer, E Ruppin Molecular Cancer Therapeutics 22 (12_Supplement), LB_B06-LB_B06, 2023 | | 2023 |
Eytan RuppinChief, Cancer Data Science Lab (CDSL), NCI/NIHVerified email at nih.gov
